Literature DB >> 22404486

High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures.

K-L Goh1, J Manikam, C-S Qua.   

Abstract

BACKGROUND: H. pylori eradication failures are difficult to treat and rescue therapies often consist of complex treatment regimens. AIM: To determine an effective and practical rescue therapeutic strategy for H. pylori treatment failures using two consecutive regimens: first rescue therapy - rabeprazole 20 mg t.d.s. and amoxicillin 1 g t.d.s. for 2 weeks and for failures a further second rescue therapy - rabeprazole 20 mg b.d., levofloxacin 500 mg b.d., amoxicillin 1 g b.d. for a further 2 weeks.
METHODS: Consecutive patients who failed the proton pump inhibitor (PPI) 1-week triple therapy were recruited for the study. H. pylori status was determined by a C(13) urea breath test.
RESULTS: One hundred and forty-nine patients received the first rescue therapy. Seven were not compliant to medication/defaulted follow-up. Eradication success- first rescue therapy: per protocol (PP) analysis-107/142 (75.4%) (95% CI (68.3-82.4%) and intention to treat (ITT) analysis-107/149 (71.8%) 95% CI (64.6-79.0%). Thirty-one of 35 patients who failed the first rescue therapy received the second rescue therapy. All were compliant with medications. Eradication success- PP and ITT was 28/31 (90.3%) 95% CI (74.2-98.0%). The cumulative eradication rate using both rescue therapies: PP analysis- 135/138 (97.8%) 95% CI: (93.8-99.6%), ITT analysis- 135/149 (90.6%) 95% CI: (84.7-94.8%).
CONCLUSIONS: A 2-week high dose PPI-amoxicillin dual therapy followed by a PPI-amoxicillin-levofloxacin triple therapy were highly successful in achieving eradication in H. pylori treatment failures.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22404486     DOI: 10.1111/j.1365-2036.2012.05054.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  12 in total

1.  Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study.

Authors:  Hideki Mori; Hidekazu Suzuki; Juntaro Matsuzaki; Hitoshi Tsugawa; Seiichiro Fukuhara; Sawako Miyoshi; Kenro Hirata; Takashi Seino; Misako Matsushita; Toshihiro Nishizawa; Tatsuhiro Masaoka; Takanori Kanai
Journal:  United European Gastroenterol J       Date:  2015-11-13       Impact factor: 4.623

2.  Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy.

Authors:  Omero Alessandro Paoluzi; Giovanna Del Vecchio Blanco; Emanuela Visconti; Manuela Coppola; Carla Fontana; Marco Favaro; Francesco Pallone
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

3.  Helicobacter pylori Antimicrobial Susceptibility Testing-Guided Salvage Therapy in the USA: A Real Life Experience.

Authors:  Bei Tan; Jyh-Chin Yang; Carol L Young; Shrinivas Bishu; Stephanie Y Owyang; Mohamad El-Zaatari; Min Zhang; Helmut Grasberger; Jia-Ming Qian; John Y Kao
Journal:  Dig Dis Sci       Date:  2017-12-20       Impact factor: 3.199

4.  Sex-Specific Risk Factors Associated with Helicobacter pylori Infection Among Individuals Undergoing Health Examinations in China.

Authors:  Yumei Wu; Hui Zeng; Meiping Zhang; Chunyan Li; Yuanlin Tang; Xiufen Li; Shanyou Yuan; Qifeng Wei; Jinghua Wang; Xianjia Ning; Xiaoyin Zhang
Journal:  Int J Gen Med       Date:  2022-06-29

Review 5.  Treatment of Helicobacter pylori infection: Current and future insights.

Authors:  Maliheh Safavi; Reyhaneh Sabourian; Alireza Foroumadi
Journal:  World J Clin Cases       Date:  2016-01-16       Impact factor: 1.337

Review 6.  Treatment of Helicobacter pylori infection: current status and future concepts.

Authors:  Jyh-Chin Yang; Chien-Wei Lu; Chun-Jung Lin
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

Review 7.  Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance.

Authors:  Yi Hu; Yin Zhu; Nong-Hua Lu
Journal:  Front Cell Infect Microbiol       Date:  2017-05-05       Impact factor: 5.293

8.  Current status of Helicobacter pylori resistance to Clarithromycin and Levofloxacin in Malaysia-findings from a molecular based study.

Authors:  Suat Moi Puah; Khean Lee Goh; Heng Kang Ng; Kek Heng Chua
Journal:  PeerJ       Date:  2021-06-09       Impact factor: 2.984

9.  Functional and molecular surveillance of Helicobacter pylori antibiotic resistance in Kuala Lumpur.

Authors:  Xinsheng Teh; Yalda Khosravi; Woon Ching Lee; Alex Hwong Ruey Leow; Mun Fai Loke; Jamuna Vadivelu; Khean Lee Goh
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

10.  Efficacy of Levofloxacin Based Triple and High-Dose PPI-Amoxicillin Dual Eradication Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies.

Authors:  Kenichiro Okimoto; Makoto Arai; Keiko Saito; Shoko Minemura; Daisuke Maruoka; Tomoaki Matsumura; Tomoo Nakagawa; Tatsuro Katsuno; Chisato Ishii; Shota Murata; Masaharu Watanabe; Fumio Nomura; Osamu Yokosuka
Journal:  Int Sch Res Notices       Date:  2014-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.